Mode
Text Size
Log in / Sign up

Kawasaki disease

Part of Vasculitis

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Kawasaki disease

7 trials tracked for Kawasaki disease: 2 in phase 3 or 4.

7Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Phase 2 3 Phase 1 2
  1. Phase 3 Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Completed
  2. Phase 3 A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Completed
  3. Phase 2 A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease Completed
  4. Phase 2 Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Completed
  5. Phase 2 Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Completed
  6. Phase 1 Infliximab (Remicade) for Patients With Acute Kawasaki Disease Completed
Show 1 more trials
  1. Phase 1 Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Kawasaki disease

What lab factor helps predict coronary lesions in children with Kawasaki disease?

Routine lab indicators like C-reactive protein and erythrocyte sedimentation rate help predict coronary artery lesions in children with Kawasaki disease.

Full answer →
Does adding prednisolone help reduce coronary artery lesions in newly diagnosed patients?

No, adding prednisolone to standard treatment did not significantly reduce coronary artery lesions at 1 month in newly diagnosed Kawasaki disease patients, according to a large randomized trial.

Full answer →
Can a machine-learning model predict if a child will have coronary artery lesions?

Yes, machine-learning models can predict coronary artery lesions in children with Kawasaki disease, with some achieving high accuracy (AUC up to 0.95).

Full answer →